Key takeaways
- Mounjaro titration is designed to move slowly so side effects are easier to tolerate.
- Tracking weekly timing and dose changes helps you spot patterns across escalation phases.
- Dose adjustments should always follow the plan set by your prescriber.
Quick answer
A simple step-by-step view of the Mounjaro titration schedule and what changes as your weekly dose increases.
Mounjaro titration starts at 2.5 mg once weekly and usually moves up every 4 weeks until you and your prescriber reach the right maintenance dose. The gradual schedule is there to make side effects easier to tolerate, not because 2.5 mg is meant to be the long-term dose.
What is the Mounjaro dose titration schedule?
The FDA-approved titration schedule for Mounjaro follows a step-wise approach. Each dose is taken once weekly by subcutaneous injection, and increases happen in 2.5 mg increments after a minimum of 4 weeks on the current dose. Your healthcare provider determines the target maintenance dose based on your individual response and tolerability.
| Weeks | Dose | Purpose |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Initiation (not a treatment dose) |
| Weeks 5–8 | 5 mg | First maintenance dose option |
| Weeks 9–12 | 7.5 mg | Intermediate step |
| Weeks 13–16 | 10 mg | Second maintenance dose option |
| Weeks 17–20 | 12.5 mg | Intermediate step |
| Week 21+ | 15 mg | Maximum maintenance dose |
According to the FDA prescribing information, the 2.5 mg dose is intended for treatment initiation and is not effective for glycemic control or weight management on its own. The first clinically effective dose is 5 mg once weekly.
How does Mounjaro work in the body?
Mounjaro (tirzepatide) is the first FDA-approved dual GIP/GLP-1 receptor agonist. Unlike medications such as Wegovy or Ozempic that target only the GLP-1 receptor, tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.
This dual action stimulates insulin release from the pancreas when blood sugar is elevated, reduces glucagon secretion (which lowers the liver's glucose output), slows gastric emptying, and helps reduce appetite. Research published in the Journal of Clinical Investigation found that tirzepatide has a higher affinity for the GIP receptor — comparable to native GIP — while its affinity for the GLP-1 receptor is approximately 18- to 20-fold weaker than native GLP-1. This "imbalanced agonism" may contribute to its effectiveness.
Tirzepatide has an elimination half-life of approximately 5 days (around 120 hours), which supports once-weekly dosing. Steady-state plasma concentrations are typically reached after 4 weeks of weekly administration, according to pharmacokinetic data from the FDA review.
What weight loss results can be expected at each dose?
The SURMOUNT-1 trial — a phase 3, double-blind, randomized, placebo-controlled trial of 2,539 adults with obesity or overweight — showed significant weight loss across all tirzepatide dose levels over 72 weeks.
| Dose | Average weight loss | Patients losing 5%+ body weight |
|---|---|---|
| 5 mg | 16.0% (~35 lb / 16 kg) | 85% |
| 10 mg | 21.4% (~49 lb / 22 kg) | 89% |
| 15 mg | 22.5% (~52 lb / 24 kg) | 91% |
| Placebo | 2.4% (~5 lb / 2 kg) | 35% |
These results were published in the New England Journal of Medicine in 2022. It is important to note that individual results vary, and participants in the trial also followed a reduced-calorie diet and increased physical activity. Talk to your healthcare provider about what results may be realistic for your situation.
What side effects occur at each dose level?
Gastrointestinal side effects are the most commonly reported adverse reactions with Mounjaro, and they follow a dose-dependent pattern. In pooled clinical trial data, the overall rate of gastrointestinal adverse events was 37.1% at 5 mg, 39.6% at 10 mg, and 43.6% at 15 mg, compared with 20.4% for placebo.
| Side effect | 5 mg | 10 mg | 15 mg | Placebo |
|---|---|---|---|---|
| Nausea | ~13% | ~18% | ~24% | ~4% |
| Diarrhea | ~13% | ~17% | ~21% | ~9% |
| Vomiting | ~6% | ~8% | ~14% | ~2% |
| Decreased appetite | ~7% | ~10% | ~12% | ~2% |
The majority of nausea, vomiting, and diarrhea episodes occurred during dose escalation and decreased over time, according to the FDA prescribing information. Discontinuation rates due to gastrointestinal side effects were 3% at 5 mg, 5.4% at 10 mg, and 6.6% at 15 mg.
How can you manage side effects during titration?
Many healthcare providers recommend a few practical strategies to reduce gastrointestinal discomfort during Mounjaro dose escalation. Eating smaller, more frequent meals instead of large portions may help reduce nausea. Avoiding high-fat and fried foods is also commonly suggested, as these can worsen stomach symptoms when gastric emptying is slowed.
Staying hydrated is especially important if you experience diarrhea or vomiting. Some providers suggest eating bland foods such as crackers, toast, or rice during the first few days after an injection, when side effects tend to peak.
If side effects at a particular dose are severe or persistent, your healthcare provider may recommend staying on the current dose for an additional 4 weeks before increasing, rather than moving up on schedule. The prescribing information states that dose increases should happen after "at least 4 weeks," meaning it is safe to remain on a given dose longer if needed. Never adjust your dose without consulting your provider.
What should you do if you miss a Mounjaro dose?
According to the FDA prescribing information, if you miss a dose of Mounjaro, take it as soon as possible within 4 days (96 hours) of the missed dose. If more than 4 days have passed, skip the missed dose and take your next dose on your regular scheduled day.
It is important not to take two doses of Mounjaro within 3 days (72 hours) of each other. After taking a late dose, you can then resume your regular once-weekly schedule. If you frequently miss doses, consider setting a weekly reminder or using a tracking app like Glone to stay on schedule and keep a record of your injection history.
How does the Mounjaro titration compare to other GLP-1 medications?
Mounjaro's titration differs from semaglutide-based medications in both the starting dose and the number of escalation steps. Here is a comparison of common GLP-1 titration schedules:
| Medication | Starting dose | Maximum dose | Titration steps | Time to max dose |
|---|---|---|---|---|
| Mounjaro (tirzepatide) | 2.5 mg | 15 mg | 6 steps | ~20 weeks |
| Ozempic (semaglutide) | 0.25 mg | 2 mg | 4 steps | ~8–12 weeks |
| Wegovy (semaglutide) | 0.25 mg | 2.4 mg | 5 steps | ~16–20 weeks |
Because Mounjaro has more dose levels and a wider range, the titration can take longer. However, many people begin to see results before reaching the maximum dose. In the SURMOUNT-1 trial, participants on the 5 mg dose — the lowest maintenance level — still achieved an average weight reduction of 16%. Your provider will help determine the right maintenance dose for you.
What tips help you stay on track during titration?
Mounjaro titration lasts at least 20 weeks if you go all the way to 15 mg, so staying organized matters. Inject on the same day each week to build a consistent routine. You can administer Mounjaro at any time of day, with or without food.
Rotate your injection site between the abdomen, thigh, and upper arm to reduce the chance of injection-site reactions. A tracking tool like Glone can help you log which site you used last and remind you when your next injection is due — which is especially helpful during dose changes when it's easy to lose track of your schedule. If you want a product view built specifically around this weekly tirzepatide routine, see the Glone Mounjaro tracker page.
Keep your Mounjaro pen in the refrigerator at 36°F to 46°F (2°C to 8°C) before first use. An unused pen can be stored at room temperature (up to 86°F / 30°C) for up to 21 days if needed. Do not freeze the pen, and do not use it if the solution appears cloudy or contains particles.
Sources
- FDA Prescribing Information for Mounjaro (tirzepatide) — accessdata.fda.gov
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. — pubmed.ncbi.nlm.nih.gov
- Thomas MK, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. — insight.jci.org
- Tirzepatide — StatPearls, NCBI Bookshelf — ncbi.nlm.nih.gov
- Eli Lilly SURMOUNT-1 Press Release — investor.lilly.com